E2F4DN Transgenic Mice: A Tool for the Evaluation of E2F4 as a Therapeutic Target in Neuropathology and Brain Aging (2022)
Research
We’re pioneering innovative gene therapies for neurodegenerative diseases through a multifactorial mechanism of action
Pipeline
A radically new approach with a significant impact on neurodegenerative diseases
Scientific Team
A scientific team added by researchers with over 30 years of expertise in neuroscience
Based in Madrid and Valencia, Tetraneuron emerges as a spin-off from the Cajal Institute, affiliated with the Spanish National Research Council (CSIC)
We’re in the process of developing gene therapies aimed at addressing neurodegenerative conditions. These treatments have been devised to reinstate biological processes that have been impacted by the pathogenic phosphorylation of E2F4.
Our gene therapy based on E2F4DN is a promising approach for Alzheimer’s disease
A method to ascertain the early risk of developing Alzheimer’s disease
We introduce a profoundly innovative approach that holds the promise of transformative impact on brain health
E2F4DN Transgenic Mice: A Tool for the Evaluation of E2F4 as a Therapeutic Target in Neuropathology and Brain Aging (2022)
A Mutant Variant of E2F4 Triggers Multifactorial Therapeutic Effects in 5xFAD Mice (2022)
E2F4 as a single multifactorial target against Alzheimer’s disease (2021)
The scientific team has members with over 30 years of experience in neuroscience, along with executives from biopharmaceutical companies as partners.
Scientific Board Member
Scientific Board Member
Scientific Director and co-Founder
Managing Director
R&D Director
Technical Director
Board Member
Senior Researcher
Researcher
Laboratory Technician
Laboratory Technician
Strategic Advisor
Strategic Advisor
Strategic Advisor
PhD. Student
TETRANEURON
Check out our participation in the launch of ComunidadDesafia! ?
We’re excited to be part of this dynamic community and look forward to the opportunities and collaborations ahead.
TETRANEURON
We had the privilege of attending the EMEA Summit as part of the JLabs family. ?✨
Johnson & Johnson Innovation – JLABS is a global life science network offering startups like ours access to expertise, a vibrant community, essential industry connections, and comprehensive entrepreneurial programs.
Being a part of this dynamic network accelerates our mission and amplifies our impact in the life sciences sector.??
TETRANEURON
Yesterday, we had an inspiring partner meeting at TETRANEURON , reaffirming our commitment to pioneering innovative gene therapies for neurodegenerative diseases. We extend our gratitude to our partners for their ongoing support. Together, we are making a difference!? #GeneTherapy #NeurodegenerativeDiseases #Innovation#Tetraneuron
TETRANEURON
? Exciting News! ? We’re thrilled to announce that we’ll be attending the RESI Europe conference in Barcelona on June 19th! Our team is excited to present our innovative project to international investors. Let’s connect and explore opportunities at RESI Europe. See you in Barcelona! ? #RESIEurope #Barcelona #Innovation #Investment #Networking
TETRANEURON
https://www.linkedin.com/posts/tetraneuron_tetraneuron-genetherapy-activity-7183463740216885248-vUp3
TETRANEURON
Embracing Change in 2024: We’re giving our website a fresh new look! Join us on this exciting journey to stay in the loop with all things Tetraneuron. Don’t miss out on the latest from Tetraneuron ? https://tetraneuron.com #TetraneuronUpdates #genetherapy
TETRANEURON
Last week, we had a really interesting session with our SAB Member Alvaro Pascual-Leone. Definitely, we have a lot of promising options to explore for our therapy now. Big thanks to Alvaro for sharing his talent with us! #genetherapy #Alzheimer #innovation #braindiseases
TETRANEURON
?? BIG NEWS! ???? We’re proud to announce a major milestone for TETRANEURON ! Our new corporate headquarters in Madrid is officially open, marking a significant step in our journey. ? . This dynamic space, in the heart of Madrid, has been designed to inspire collaboration, innovation, and growth towards developing life-changing gene therapies for neurodegenerative diseases. Join us on this incredible path at our stunning location: ? C/Velázquez 154, Madrid. ✨ We can’t wait to welcome you to our new space! ? #Tetraneuron #genetherapy #innovation #bignews
TETRANEURON
Fascinating piece by Expansión discussing the power of patents in companies like TETRANEURON . We’re all about robust IP for every innovation we craft? Thank you, Alive comunicación! ? #patents #genetherapy
TETRANEURON
We were delighted to have the opportunity to speak at #Biozell‘s #InvestorDay. Such events are pivotal in highlighting the innovation within the Spanish biotech sector. It was a pleasure to share the stage with other remarkable projects! #bioval #tetraneuron #alzheimer #genetherapy
TETRANEURON
Excited to welcome amazing investors like Biozell! ? Mark your calendar for October 17th. During the Investor’s Day, they will present their ongoing ventures and brand-new investment possibilities. We’re thrilled to showcase our project at this event. Don’t miss this opportunity to join it! #investment #alzheimer #genetherapy
TETRANEURON
Great day at #BioRNConference, Next-Generation Cell and Gene Therapies. #genetherapy #alzheimer
TETRANEURON
It was a pleasure attending the event “CERCO AL ALZHEIMER” at the Universidad Europea of Madrid. Our Scientific Advisor, Teodoro Del Ser Quijano, led an engaging discussion on therapeutic advancements and their current status. A remarkable event during the #Alzheimer‘s month 2023 #Alzheiemer #genetherapy
TETRANEURON
Meet us at #BIOSPAIN2023 in Barcelona ! Just a few days left to interact with experts, companies and investors from all over the world. Find our colleagues Maria del Mar Municio, Ph.D and M.Carmen Alvarez Abril at the partnering area. See you there! #Alzheimer #genetherapy
TETRANEURON
Exciting News! Join us at #IBRO2023 Conference. Our colleagues Cristina Sánchez-Puelles, PhD and Morgan Ramón Landreau will be presenting our amazing research on Alzheimer’s Disease. Visit us! ?Poster B28 ?Poster B03 #genetherapy #Tetraneuron #alzheimer
TETRANEURON
Great news! Congratulations to Maria del Mar Municio, Ph.D for her incorporation as R&D Director at TETRANEURON .Undoubtedly, her experience and leadership will further drive the innovation and development of the company. #Tetraneuron #Innovation #Leadership #alzheimer #genetherapy
TETRANEURON
Delighted by the industry’s progress! ? Yet, Alzheimer’s Drug Discovery Foundation reminds us to explore diverse pathways for more effective treatments. Our promising therapy targets key areas to make a difference. #Alzheimers #genetherapy #Tetraneuron
TETRANEURON
Muchas gracias #Valenciaplaza por haceros eco de esta importante noticia para #Tetraneuron Estamos encantados de contar con #Biozellventures como nuevo socio y contar con el enorme talento y experiencia de Angela Perez y su equipo. ¡Seguimos! ????? #genetherapy #alzheimersdisease #advancedtherapies #parkinson #biotech
TETRANEURON
Muchas gracias #Mendelbrain por haceros eco de esta importante noticia para #Tetraneuron ¡Seguimos! #terapiagenica #genetherapy #cns #snc #alzheimers #parkinson #aging #innovation #biotech #advancedtherapies
TETRANEURON
Great news!? Biozell Ventures, the investment arm of BIOHUB VLC, is betting on Tetraneuron’s new gene therapy for Alzheimer’s disease. Please join us in welcoming our newest investors to the Tetraneuron family! #alzheimer #genetherapy
TETRANEURON
The Alzheimer’s Association®International Conference (AAIC)- the most relevant conference on #alzheimer– starts next Sunday, 16 July, in Amsterdam! The Tetraneuron team is looking forward to joining researchers and clinicians to discuss the latest advances in the field. Several team members will present a poster during the event! – José María Frade. Scientific Director – Cristina Sánchez-Puelles, PhD. Senior Researcher – Morgan Ramón Landreau. Researcher Visit our posters or meet the team to learn more about our therapy TET-101. See you in #AAIC2023! #Tetraneuron #alzheimer #genetherapy
We invite you to join this new path for neurodegenerative diseases
A new path for neurodegenerative diseases
Contact
VALENCIA
BIOHUB VLC
Travesía s/n 15 E Base 5,
46024 Valencia
MADRID
C/ Velázquez, 154 – Pta Baja Izda A , 28002 Madrid
VALENCIA
BIOHUB VLC
Travesía s/n 15 E Base 5,
46024 Valencia
MADRID
C/ Velázquez, 154 – Pta Baja Izda A , 28002 Madrid
